New combo therapy shows promise for early lung cancer
NCT ID NCT03110978
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding an immunotherapy drug (nivolumab) to precise, high-dose radiation therapy helps prevent lung cancer from coming back in people with early-stage non-small cell lung cancer. About 140 participants will receive either radiation alone or radiation plus immunotherapy. The goal is to see if the combination improves how long people stay cancer-free.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG ATYPICAL CARCINOID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
-
MD Anderson West Houston
Houston, Texas, 77079, United States
-
MD Anderson in The Woodlands
Conroe, Texas, 77384, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a black seed extract boost immunotherapy against a rare cancer?
- Radiation hotspots may boost lung cancer treatment — a trial puts it to the test
- New drug cocktail aims to fight rare cancer
- Double-Action antibody takes on Hard-to-Treat neuroendocrine cancers
- Two-Drug combo aims to stall rare gut tumors
- Could a muscle relaxant help fight lung cancer? scientists test papaverine with standard therapy